Table 2 Clinical and biochemical features between patients with nonfunctioning adrenal tumors (NFAT) with cortisol after dexamethasone suppression test (F-1mgDST) levels < 1.2 µg/dL and NFAT patients with F-1mgDST levels ≥ 1.2 µg/dL
All patients (n = 615) | Patients with F-1mgDST levels < 1.2 µg/dL (n = 289) | Patients with F-1mgDST levels ≥ 1.2 µg/dL (n = 326) | P value | |
|---|---|---|---|---|
Females | 289 (47.0) | 182 (63.0) | 195 (59.8) | 0.456 |
Age (yrs) | 60.15 ± 11.8 (21.0–85.7) | 57.5 ± 12.3 (25.0–85.7) | 62.5 ± 10.9 (21.0–85.0) | < 0.001 |
BMI (kg/m2) | 28.5 ± 4.9 (18.3–50.0) | 28.9 ± 5.2 (18.3–50.0) | 28.1 ± 4.6 (18.4–43.3) | 0.06 |
ACTH (pg/mL) | 16.4 ± 11.1 (1.0–60.0) | 17.7 ± 11.9 (1.3–60.0) | 15.3 ± 10.1 (1.0–60.0) | 0.008 |
F-1 mg-DST (µg/dL) | 1.17 ± 3.80 (0.10–1.80) | 0.83 ± 0.22 (0.10–1.10) | 1.46 ± 0.19 (1.20–1.80) | < 0.001 |
Size of adenoma (cm) | 2.2 ± 0.9 (1.0–6.0) | 2.0 ± 0.8 (1.0–6.0) | 2.4 ± 0.9 (1.0–6.0) | < 0.001 |
Pts with HT (%) | 281 (45.7) | 110 (38.1) | 171 (52.5) | < 0.001 |
Pts with DM (%) | 114 (18.5) | 38 (13.1) | 76 (23.3) | 0.001 |
Pts with HT plus DM (%) | 79 (12.8) | 24 (8.3) | 55 (16.9) | < 0.002 |
Pts with OB (%) | 212 (34.5) | 99 (34.3) | 113 (34.7) | 0.932 |
Pts with DL (%) | 176 (28.6) | 85 (29.4) | 91 (27.9) | 0.721 |
Pts with CVE (%) | 33 (10.5) | 10 (3.2) | 23 (7.3) | 0.028 |